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Purpose: To identify and functionally characterize the mutation responsible for autosomal dominant retinitis pigmentosa
(adRP) in a large, six-generation French family.
Methods: Twenty individuals from this family participated in the genetic investigation. Six affected and 14 unaffected
individuals from three-generations were available for linkage analysis using microsatellite markers flanking the rhodopsin
(RHO) gene. A two-point logarithm of odds (LOD) score calculation was undertaken using GENEMARKER and MLINK
software. Sanger sequencing of RHO was performed. Cellular localization of the mutant protein was performed by
transforming SK-N-SH cells with pEGFP-N1-Rho, pEGFP-N1-Rho(P23H), and pEGFP-N1-Rho(c.614–622del).
Results: The proband had nyctalopia, visual field constriction, peripheral bone spicule pigmentation of the fundus, central
acuity (6/24 RE; 6/12 LE) at 55 years of age. Linkage analysis of this family suggested RHO as a possible candidate since
the flanking marker D3S1292 yielded a LOD score of 2.43 at θ=0. Cloning of an exon 3 PCR product and direct sequencing
of single clones identified a novel deletion in the third exon of RHO, c.614–622del (p.Y206-F208del). The deleted mutant
protein localized to the endoplasmic reticulum and formed inclusion bodies.
Conclusions: This novel deletion in exon 3 of the RHO gene, c.614–622del results in a classical form of adRP in a multi-
generation French family. Protein expression analyses confirmed that the deletion led to protein misfolding and suggest
this is a class II mutation, similar to P23H, the most common class II mutation seen in North America.
Retinitis  pigmentosa  (RP)  has  a  prevalence  of  about
1:4,000 and is the most frequent form of inherited peripheral
retinal degeneration [1]. Multiple modes of inheritance have
been reported, and over 45 causative genes have now been
identified (RetNet). Rhodopsin (RHO) mutations are one of
the most common causes of RP in humans (8%–10%) [2,3].
They account for a quarter of all autosomal dominant RP
(adRP) cases (RetNet), but autosomal recessive inheritance
has  also  been  described  [4,5].  Mutations  in  RHO  are
associated with a range of phenotypes including mild to severe
RP, sector RP, and rare cases of congenital stationary night
blindness [5–7].
In the early 1990s, Sung et al. [8] and Kaushal et al. [9]
proposed a classification of RHO mutations according to the
localization of the mutant protein and its capacity to bind 11-
cis-retinal. Class I mutations predominantly occur in the C-
terminal of the protein, are able to bind to 11-cis-retinal, and
form a functional chromophore. In contrast, class II mutations,
which occur in the intradiscal, transmembrane or cytoplasmic
domains of the protein, result in misfolding of the protein and
make it unable to bind to 11-cis-retinal. Class II mutations are
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more common. In a recent review, Mendes et al. [10] proposed
an  extended  classification  of  RHO  mutations,  expanding
RHO mutations into five further subgroups according to their
intracellular  and  biochemical  behavior.  According  to  this
nomenclature,  the  most  common  cause  of  adRP  in  North
America, P23H, is a class II mutation. The mutant protein is
retained  in  the  endoplasmic  reticulum  (ER)  and  does  not
reconstitute with 11-cis-retinal.
In this study, we report a novel in-frame RHO deletion
identified in a large, French family with adRP. The cellular
localization of the deleted mutant protein is presented and
compared with the common P23H mutation.
METHODS
Recruitment  of  patients  and  phenotype  analysis:  A  six-
generation  French  family  with  17  members  affected  with
adRP participated in this study. Informed consent for genetic
investigation was obtained from 20 subjects (6 affected and
14  unaffected;  Figure  1)  in  accordance  with  guidelines
established by the Declaration of Helsinki. This project was
approved by the Institutional Review Board at Hôpital des
Enfants, Dijon, France. A full medical history was captured
at  the  time  of  the  first  hospital  visit  and  ophthalmic
examinations  were  performed  for  all  available  family
members. The phenotype of the family is represented by the
proband (individual V.7) in this report. Visual acuity testing,
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581color  fundus  photography,  and  automated  suprathreshold
testing using the full field 120 program of the Humphrey Field
Analyzer (Zeiss, Germany) was performed. Genomic DNA
was  obtained  using  Nucleon  DNA  Isolation  Kits  for
Mammalian  Blood  according  to  the  manufacturer’s
instructions (Tepnel Life Sciences, Manchester, UK).
Mutation detection:
Linkage  analysis—Microsatellite  markers  flanking
known genes for adRP were selected from the ABI Prism
Linkage Mapping Set v 2.5 (Applied Biosystems, Foster City,
CA) and the Ensembl database. Sequences are available on
request. PCRs were performed with the Absolute QPCR kit,
accordingly  to  the  manufacturers’  instructions  (ABgene,
Epsom, UK). The resultant PCR products were diluted in HiDi
formamide containing GeneScanTM-500 LIZ ® fluorescent
dye  (Applied  Biosystems,  UK).  After  denaturation,  the
samples  were  loaded  on  a  DNA  sequencer  (model  3730;
Applied Biosystems [ABI], Cheshire, UK) and the genotyping
calls and Mendelian error checks were performed with the
GENEMARKER software (Biogene, Cambridge, UK). Two
point LOD scores were calculated using the MLINK program
[11]  with  a  parametric  linkage  model  of  autosomal
dominance,  penetrance  of  0.9,  and  with  a  disease  gene
frequency of 0.0001.
Direct DNA sequencing—The five exons and flanking
introns  of  the  RHO  gene  were  amplified  using  primers
previously described [12] and Gold Taq polymerase (ABI).
PCR products were sequenced using a BigDye terminator
sequencing  kit  ver.1.1  (ABI)  and  the  ABI  3730  DNA
Sequencer.
Cloning  of  the  mutated  allele—An  allele-specific
cloning  and  sequencing  approach  was  used  to  precisely
characterize  the  deletion.  Briefly,  exon  3  of  RHO  was
amplified  from  genomic  DNA  by  PCR  and  the  purified
amplicon was ligated, by means of a TA-ligation method, into
the  TA-cloning  vector  pGEM-T  (Promega,  Southampton,
UK),  and  was  subcloned  into  JM109  competent  cells
(Stratagene, La Jolla, CA) under normal culture conditions.
Plasmid Minipreps were prepared (Sigma-Aldrich, Dorset,
UK) and sequenced using the T7 and SP6 primers.
Localization of the mutant proteins in SK-N-SH cells: The
plasmids,  pEGFP-N1-Rho  and  pEGFP-N1-Rho(P23H),
encoding rod opsin-GFP fusion proteins have been described
previously [13]. Plasmid pEGFP-N1-Rho was used as the
template  for  generation  of  the  c.614–622del  (p.Y206-
F208del) mutant using site specific primers (5′-ACA ATG
AGT CGT TCG TCA TCG TGG TCC ACT TCA TCA TCC
C-3′ and 5′-GGG ATG ATG AAG TGG ACC ACG ATG
ACG AAC GAC TCA TTG T-3′) and using the QuikChange
Figure 1. Pedigree of the French family recruited in Dijon. Subjects affected by autosomal dominant retinitis pigmentosa are indicated by
solid (black) symbols, while unaffected individuals are indicated by open (white) symbols. Slashed symbols represent deceased family
members. Subjects for whom samples were available for molecular analysis are labeled with an Arabic numeral. The proband is indicated by
an arrow.
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582site-directed mutagenesis kit according to the manufacturer's
instructions  (Stratagene,  La  Jolla,  CA).  The  pEGFP-N1-
Rho(Y206-F208del) plasmid was sequenced to detect any
PCR artifacts and to confirm the presence of the mutation. SK-
N-SH human neuroblastoma cells were acquired from the
European Collection of Cell Cultures and were transfected at
low passage numbers (<P20) using Lipofectamine PLUS and
according  to  the  manufacturer’s  instructions  (Life
Technologies, Paisley, UK). The subcellular distribution of
RHO (Y206-F208del) in SK-N-SH neuroblastoma cells was
compared to wild-type and P23H mutant by visualizing GFP
with epifluorescence microscopy (Nikon Eclipse 80i, Derby,
UK).  For  morphological  analyses,  three  groups  with
approximately 100 transfected cells in each were counted and
the  distribution  of  WT  opsin-GFP,  P23H  opsin-GFP,  and
Y206-F208del opsin-GFP in transfected cells was classified
either as predominantly plasma membrane, predominantly
ER, or as containing inclusions. Counts were analyzed using
the ANOVA test (ANOVAR) to compare the means of two
samples. Images were taken with a Zeiss LSM 510 confocal
microscope (Welwyn Garden City, UK).
RESULTS
Clinical phenotype: The RP in the family segregates in an
autosomal  dominant  pattern  (Figure  1).  The  phenotype
observed  was  typical  with  bone-spicule  pigmentation,
decreased  visual  acuity,  attenuation  of  the  retinal  blood
vessels, and pale optic discs and night blindness (Figure 2A).
The proband (individual V.7) was 55 years old at her last
clinical examination. Her visual acuity was 6/24 (right eye)
and  6/12  (left  eye).  She  had  already  undergone  bilateral
cataract surgery. Severe constriction of the visual field was
recorded on the 120-point Humphrey screening test (Figure
2B). Her husband and son had normal fundal examinations.
The first cousin of the proband, individual V.9, had bone
spicule pigmentation of his fundus at the last follow-up visit
at 50 years of age, with macular atrophy resulting in visual
acuities of 6/60 in the right eye and 6/18 in the left eye. He
was registered partially sighted at that visit. His affected son
developed early peripheral retinal signs suggestive of RP at
the age of 11 years, and was diagnosed at the age of 15 years.
He maintained good visual acuities of 6/9 in the right eye and
6/12 in the left eye at the age of 21 years. Individual V.11
(visual acuities of 6/6 bilaterally), and VI.20 had a normal
ophthalmic examination. Individual V.16 had moved away
from France but was known to have lost sight, presumably
from RP. The attending family members corroborated the
family history and affected status of those who send blood
samples but did not attend for clinical examination.
Linkage to chromosome 3: The search for the causal mutation
segregating the family began by testing known adRP genes
and loci using a targeted and cost-effective method of linkage
analysis and commercially available microsatellite markers.
The  linkage  analysis  of  the  20  participants  (numerically
indicated in Figure 1) generated a two-point LOD score of
2.43 at θ=0 for marker D3S1292, located 2Mb 3′of the RHO
gene. Although not statistically significant, this result was
suggestive of linkage to the RHO locus as it is the most
common causative gene in adRP families. All five exons of
the RHO gene were sequenced for individuals 9 and 13. A
sequence  aberration  was  detected  in  exon  three  for  both
individuals, but was difficult to identify properly, indicating
it could be a deletion or an insertion. To characterize this
change, we isolated the sequences by allele-specific cloning.
Nine base-pair deletion in exon 3 of the RHO gene: Cloning
of both PCR fragments (wild type and mutant) from individual
9 identified a novel mutation in the RHO gene: a nine base-
pair deletion from nucleotide 614 to nucleotide 622 in exon
three, c.614–622del (Figure 3). The in silico analysis of the
mutant sequence predicts deletion of amino acid 206 to 208,
which are tyrosine, methionine, and phenylalanine (p.Y206-
F208del). The mutation co-segregated with the disease: it was
identified in all six participants with a positive history or
clinical signs of RP, but none of the unaffected individuals
were carriers of this change.
Localization of the mutant protein in SK-N-SH cells: The
neuroblastoma derived cell line, SK-N-SH, have been used
previously to study the heterologous expression of mutant rod
opsins [14–16], therefore, SK-N-SH cells were transfected
with  pEGFP-N1-Rho,  pEGFP-N1-Rho(P23H),  or  pEGFP-
N1-Rho(c.614–622del),  encoding  wild-type  (WT)  opsin-
GFP,  P23H  opsin  GFP,  and  Y206-F208del  opsin-GFP,
respectively. Rod opsin expression has been investigated in a
range of cultured cell types and it is well documented that WT
rod opsin translocates to the plasma membrane in the absence
of an outer segment [8,9,13–16]. In the present experiment,
WT  opsin-GFP  localized  predominantly  to  the  plasma
membrane with some staining in the ER and Golgi network,
indicating the normal biogenesis and transportation of the
protein to the membrane (Figure 4A). By contrast, the P23H
opsin-GFP and Y206-F208del opsin-GFP mutants were not
trafficked  to  the  plasma  membrane  and  accumulated
intracellularly. The pattern of Y206-F208del rod opsin-GFP
fluorescence was reticular and was excluded from the nucleus
in a manner similar to the pattern for P23H rod opsin, which
is ER retained [13–16], suggesting ER retention of the in-
frame deletion mutant. Both mutants also formed intracellular
inclusion bodies (indicated by arrows). The effect of the in-
frame  deletion  mutation  on  the  proportion  of  opsin-GFP
expressing cells with inclusions was quantified (Figure 4B).
Approximately 9% of cells expressing wild-type opsin-GFP
contained inclusions 24 h after transfection and 2% were
predominantly retained in the ER. The incidence of inclusions
or ER retention rose to 31% and 69%, respectively, for cells
expressing P23H mutant rhodopsin-GFP, in accordance with
previously published data [14–16]. The Y206-F208del opsin-
GFP mutant resembled the P23H mutant with approximately
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58334%  of  cells  expressing  Y206-F208del  rod  opsin-GFP
bearing inclusions 24 h after transfection and 66% with an ER
pattern of fluorescence. Y206-F208del rod opsin-GFP was not
detected on the plasma membrane in any transfected cells.
DISCUSSION
In this publication, we report a novel nine base-pair (bp)
deletion in a six-generation French family presenting with
classical adRP. Prior to this study, 10 small deletions (Retinal
International database) had been reported in the RHO gene,
out  of  which,  four  are  multiples  of  three  nucleotides  and
therefore do not create frameshift. The c.614–622del (p.Y206-
F208del) mutation reported here is the first small deletion
found in the third exon of the gene. Keen et al. [17] described
an in-frame 12 bp deletion in exon 1, c.204–215del (p.R68-
N72del) in a small English pedigree, who presented with a
mild phenotype and relatively good visual field preservation
in the fourth decade of life. Inglehearn et al. [12] reported a
family  with  a  three  bp  deletion  in  exon  4,  c.768–770del
(p.I255del). Affected individuals from this family reported
symptoms  of  RP  early  in  life  but  had  good  visual  field
Figure  2.  Clinical  information  on  the
proband. A: Fundus photography of the
right eye shows classical bony-spicules,
attenuated vessels, and waxy pale optic
discs. B: Results of a120-point visual
field  screening  showing  severe
constriction of both visual fields. In this
automatic  visual  field  examination
(screening  test),  visual  stimuli  were
presented  in  different  points  of  the
visual field (throughout a virtual map
shown  here).  White  circles  (in  the
center) represent stimuli detected by the
proband,  whereas  black  rectangles
correspond to undetected stimuli.
Molecular Vision 2012; 18:581-587 <http://www.molvis.org/molvis/v18/a63> © 2012 Molecular Vision
584preservation in the fourth decade of life and good visual acuity
was retained until the seventh decade of life. The phenotypes
described  for  those  families  support  our  present  findings,
suggesting that in-frame small deletions induce a classical,
moderate  form  of  RP  which  progresses  slowly  with  age.
Individuals V.7 and V.9 of the family carrying the novel c.
614–622del  (p.Y206-F208del)  that  we  presented  here
maintained moderate visual function into the fifth decade of
life. It is worth noting that Farrar et al. [18] reported a missense
mutation resulting in a methionine to arginine change at codon
207, which is the middle codon of the deletion in our family
(codons 206–208). The phenotype reported for that family had
a very early onset (within the first decade of life), and ERG
cone responses were only retained until the third decade. This
small  group  of  families  displays  an  older  age  of  visual
preservation and less severe clinical characteristics in small
in-frame deletions (including multiples of three) compared to
the family with the p.M207R missense mutation. There is
significant clinical and genetic heterogeneity in families with
RHO-associated RP.
The novel deletion described in this report, c.614–622del
causes the deletion of Y206, M207, and F208. Throughout the
53 species reported in the ensemble database with complete
rhodopsin sequences (Ensembl database), the sequence YMF
is conserved in 50 species, suggesting that the three amino
acids considered separately are necessary for the function of
the protein. In the wild type sequence, Y206, M207, and F208
are part of the fifth transmembrane helices of the RHO protein.
Tyrosine and phenylalanine are amino acids containing a large
aromatic chain. Usually, aromatic chains allow secondary
folding of the protein, so it is likely that the absence of Y206
and/or  F208  disrupts  the  transmembrane  helix,  leading  to
partial or complete misfolding of the rhodopsin protein.
According to the classification of the RHO mutations
made by Sung et al. [8], Kaushal et al. [9] and more recently
by Mendes et al. [10], class II mutations result in misfolding
of the protein. Class II mutations are the most common since
the rhodopsin protein is particularly sensitive to misfolding
[19], which compromises the normal biosynthetic activity of
the secretory pathway in the inner segment. The most common
and,  therefore,  most  described  class  II  mutation  in  North
America is p.P23H. In animal models of the p.P23H mutation,
the  shortening  of  outer  segments  has  also  been  observed
[20].
c.614–622del (p.Y206-F208del) results in the deletion of
part  of  the  fifth  transmembrane  domain  of  the  rod  opsin
Figure 3. Rhodopsin mutation in exon 3.
Detection  of  the  novel  c.614–622del
(p.Y206-F208del)  mutation  in  the
RHO  gene  from  a  sequence  analysis
after  cloning  of  both  alleles.  The
electropherogram  representing  the
normal sequence is shown on top while
the deleted one is presented below.
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585protein and because of the expected alteration in secondary
folding induced by deletion of Y206 and F208, the c.614–
622del  (p.Y206-F208del)  deletion  presented  here  was
expected to induce misfolding of the protein and retention in
the ER, and therefore to be a class II mutation. To test this
hypothesis, we transfected SK-N-SH neuroblastoma cells and
compared the cellular localization of p.Y206-F208del to WT
and  p.P23H  rod  opsin-GFP  constructs.  Morphological
observation revealed that both mutant proteins accumulate in
the  ER  and  form  inclusion  bodies.  The  p.Y206-F208del
deletion reported here also formed intracellular inclusions
suggesting it is aggregation prone. Hence, similarly to p.P23H
[10,13], the novel p.Y206-F208del mutant protein belongs to
class II RHO mutations [10]. Seven other mutations in the fifth
transmembrane helix of rhodospin have been identified. Two
of the mutations (p.H211F and p.C222R; Ensemble database)
have been characterized as class II mutations, confirming that
mutations in transmembrane domains are likely to induce
misfolding of the protein.
The intracellular fate of mutant rhodopsin molecules is a
very important factor for gaining a full appreciation of the
consequences  and  mechanism(s)  of  RHO-associated  RP.
Identification and characterization of RHO mutations provide
the  potential  to  enhance  our  phenotype-genotype
understanding, and improve molecular diagnostic tools such
as microarray SNP-chips [21]. The combined use of clinical,
genetic,  and  functional  data  including  in  vitro  expression
experiments shows promise as an approach to improve our
understanding of RHO-associated pathophysiology.
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